Skip to main content
twitter
facebook
youtube
instagram
Donate to EGFR Resisters to Continue Vital Research
Hit enter to search or ESC to close
Close Search
Menu
HOME
WHO WE ARE
LEADERSHIP
OUR MISSION
EXPERT PARTNERSHIPS
YOUNG INVESTIGATORS
MEMBERSHIP
JOIN
PROJECTS & EDUCATION
ABOUT EGFR
PROJECT PRIORITY
ANNUAL RESEARCH SUMMIT
RESEARCH AWARDS
EDUCATION
NEWS
ALL NEWS
ADVOCACY
COPING & STORIES
RESEARCH & TREATMENT
SOCIAL MEDIA
INSTAGRAM
FACEBOOK
TWITTER
OUR YouTube CHANNEL
ALLIANCES & RESOURCES
MONTHLY NEWSLETTERS
LUNG CANCER ADVOCACY
BIOMARKER GROUPS
CONTACT US
DONATE
Research
Treatments
Video: Progress in the management of EGFR-mutant NSCLC in 2020: Where are we now?
By
laurabbook@gmail.com
No Comments
*July 2020*
Dr. Roy Herbst addresses this question in a video. Watch it
here
.
GIVE TODAY
DONATE
Categories
Advocacy
26
Coping With Cancer
38
Funding
9
Partners
2
Research
292
Resources
1
Stories
7
Treatments
280
STAY CONNECTED
VIEW NEWSLETTERS
You Might Like
Spira Highlights Key Advancements Across the NSCLC Treatment Paradigm in 2022
February 6, 2023
Is There a Unicorn Among the Uncommon EGFR Mutations?
February 6, 2023
Osimertinib in Non-Small Cell Lung Cancer (NSCLC) with Atypical EGFR Activating Mutations: A Retrospective Multicenter Study
February 6, 2023
Passing of The Baton—On the Death of Patient Research Advocates
February 3, 2023
Making the Most of Time Between Scans
February 3, 2023
BECOME A MEMBER
JOIN
Share
Tweet
Share
Pin
Close Menu
HOME
WHO WE ARE
LEADERSHIP
OUR MISSION
EXPERT PARTNERSHIPS
YOUNG INVESTIGATORS
MEMBERSHIP
JOIN
PROJECTS & EDUCATION
ABOUT EGFR
PROJECT PRIORITY
ANNUAL RESEARCH SUMMIT
RESEARCH AWARDS
EDUCATION
NEWS
ALL NEWS
ADVOCACY
COPING & STORIES
RESEARCH & TREATMENT
SOCIAL MEDIA
INSTAGRAM
FACEBOOK
TWITTER
OUR YouTube CHANNEL
ALLIANCES & RESOURCES
MONTHLY NEWSLETTERS
LUNG CANCER ADVOCACY
BIOMARKER GROUPS
CONTACT US
DONATE
twitter
facebook
youtube
instagram